S&P 500 Futures
(-0.08%) 5 474.25 points
Dow Jones Futures
(-0.11%) 38 776 points
Nasdaq Futures
(-0.04%) 19 913 points
Oil
(0.22%) $80.51
Gas
(1.26%) $2.82
Gold
(0.23%) $2 334.30
Silver
(-0.19%) $29.34
Platinum
(-0.21%) $968.90
USD/EUR
(0.01%) $0.932
USD/NOK
(-0.17%) $10.64
USD/GBP
(0.06%) $0.788
USD/RUB
(-1.86%) $86.81

Realaus laiko atnaujinimai MorphoSys AG [MOR]

Birža: NASDAQ Sektorius: Healthcare Pramonė: Biotechnology
Atnaujinta17 birž. 2024 @ 23:00

0.88% $ 18.30

Live Chart Being Loaded With Signals

Commentary (17 birž. 2024 @ 23:00):
Our systems believe the stock currently is undervalued by 0.07% compare to its pairs and should correct upwards.
Profile picture for MorphoSys AG

MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States...

Stats
Šios dienos apimtis 78 988
Vidutinė apimtis 375 895
Rinkos kapitalizacija 2.76B
EPS $-2.09 ( Q1 | 2024-04-30 )
Kita pelno data ( $-0.540 ) 2024-08-14
Last Dividend $0 ( N/A )
Next Dividend $0 ( N/A )
P/E -12.28
(Sector) 42.63
(Industry) 24.32
ATR14 $0.0250 (0.14%)
AADI -3.55%
ABCL -5.26%
ABCM 0.04%
ABEO -1.31%
ABIO -1.53%
ABOS -5.30%
ABSI -14.32%
ABUS -2.55%
ABVX -0.22%
ACAD -0.47%
ACER -17.95%
ACET -2.22%
ACGN 1.29%
ACHL 0.23%
ACHV 1.63%
ACIU -4.23%
ACLX -1.21%
ACRV -5.10%
ACST 0.62%
ACXP -0.42%
ADAG -5.64%
ADAP -7.23%
ADGI 0.87%
ADIL -2.29%
ADMA -1.79%
ADPT 0.32%
ADTX -7.69%
ADVM -3.94%
ADXN -6.11%
AEON 11.51%
AEZS -5.44%
AFMD -5.07%
AGEN -7.50%
AGIO -3.45%
AGLE 6.66%
AGTC 0.00%
AIKI 0.85%
AIMDW 53.45%
AKBA -1.87%
AKRO -4.46%
AKTX -6.33%
AKUS 0.00%
ALBO 0.00%
ALDX -1.34%
ALEC -2.35%
ALGS -5.76%
ALKS 2.08%
ALLK 0.86%
ALLO -2.13%
ALLR -3.01%
ALNA 3.16%
ALNY -1.93%
ALPN 0.00%
ALPX 0.00%
ALRN -0.31%
ALT -3.11%
ALVR -4.43%
ALXN 0.00%
ALXO -8.32%
ALZN -12.01%
AMRN -2.58%
AMTI -3.13%
ANAB -1.64%
ANEB -5.58%
ANGN 0.00%
ANIX -0.38%
ANL 0.61%
ANNX -4.63%
ANPC -3.15%
APGE -5.23%
APGN 8.48%
APGNW 30.65%
APLM -4.73%
APLS -3.98%
APLT -4.36%
APM 1.33%
APOP 0.38%
APRE 2.44%
APTO -3.96%
APTX 3.17%
APVO -20.53%
ARAV -13.39%
ARCT -9.26%
ARDS 20.48%
ARDX -0.94%
ARGX -2.25%
ARNA 0.00%
ARPO -0.90%
ARQT -7.76%
ARTL -0.38%
ARTLW 9.80%
ARVN -2.84%
ARWR -2.86%
ASLN -12.17%
ASMB -1.49%
ASND -2.39%
ATAI -2.19%
ATHA 2.36%
ATHE -1.61%
ATHX -33.50%
ATNF 15.09%
ATOS -4.17%
ATRA -16.93%
ATXI -1.66%
ATXS -3.50%
AUPH -1.95%
AURA 0.96%
AUTL -4.22%
AVBP -1.02%
AVEO 0.00%
AVIR -2.22%
AVRO 2.10%
AVTE -93.30%
AVTX 4.08%
AVXL -1.06%
AXLA 0.00%
AXSM 3.22%
AYLA 0.00%
AZRX 2.07%
BBI 2.17%
BBIO -2.26%
BCAB -1.89%
BCDA -2.05%
BCDAW -33.33%
BCEL -1.32%
BCLI -8.47%
BCRX 1.13%
BCTX 4.96%
BCTXW 0.00%
BCYC -4.33%
BDRX 1.89%
BDTX -8.38%
BEAM -3.38%
BFRA -2.91%
BGNE -1.97%
BIOR -10.12%
BIVI 0.41%
BLCM -6.68%
BLI -5.88%
BLPH -0.79%
BLRX -3.79%
BLTE -0.72%
BLU 0.03%
BLUE -0.77%
BMEA -9.75%
BMRN 1.81%
BNOX 1.64%
BNTC 2.46%
BNTX -3.95%
BOLD -5.95%
BOLT -0.82%
BPMC -1.59%
BPTH 10.65%
BPTS -13.47%
BRNS -6.63%
BRTX 20.00%
BTAI -2.92%
BTTX -7.50%
BTX 0.05%
BVXV 0.74%
BXRX 7.39%
BYSI 6.06%
CABA -12.20%
CADL -0.96%
CALA 60.00%
CALC -1.62%
CALT 0.03%
CAPR -4.06%
CARA -27.26%
CARM -9.65%
CASI -8.04%
CATB -6.97%
CBAY 0.03%
CBIO -2.65%
CBLI -7.31%
CBUS 3.07%
CCCC -5.48%
CCXI 0.00%
CDAK 0.00%
CDIO -1.51%
CDIOW -23.08%
CDMO 5.72%
CDMOP 0.04%
CDT -6.11%
CDTTW -47.71%
CDTX -6.32%
CDXC -0.67%
CDXS -2.30%
CELC -2.79%
CELU -2.19%
CELUW -9.52%
CERC -1.68%
CERE -0.16%
CERO -7.87%
CEROW -44.78%
CFRX -27.95%
CGEM 0.74%
CGEN -5.31%
CGON -2.68%
CGTX 0.92%
CHMA -6.00%
CHRS -2.96%
CINC 0.00%
CING -1.09%
CINGW -48.24%
CKPT -4.25%
CLBS -16.75%
CLDX 0.69%
CLGN 1.19%
CLLS -4.89%
CLNN -2.48%
CLNNW -41.25%
CLRB -9.94%
CLSD -0.84%
CLSN -0.68%
CLVS 0.00%
CMMB -24.79%
CMND 1.83%
CMPI 0.00%
CMPX 5.41%
CMRA 0.40%
CMRAW 33.33%
CMRX 1.44%
CNCE 0.00%
CNSP 3.94%
CNST 0.00%
CNTA -6.39%
CNTB 3.13%
CNTX -1.02%
COCP -0.16%
COEPW -0.66%
COGT 4.45%
CORT -1.31%
COYA -6.11%
CPRX -0.40%
CRBP -11.76%
CRBU -2.23%
CRDF -1.11%
CRGX -4.78%
CRIS 1.11%
CRNX -1.37%
CRSP -2.79%
CRTX 2.63%
CRVO -1.89%
CRVS -5.39%
CSBR 1.19%
CTCX -8.04%
CTIC 0.06%
CTMX -0.72%
CTNM 0.00%
CTXR -1.50%
CUE -1.47%
CVAC -5.18%
CVKD 3.18%
CWBR -2.55%
CYAD -12.96%
CYCC -3.55%
CYCCP -1.79%
CYCN 6.00%
CYT -2.27%
CYTK -2.13%
CYTO 2.48%
DARE -3.31%
DAWN -4.60%
DBTX -0.81%
DBVT 1.01%
DFFN 10.28%
DICE 0.06%
DMAC -0.42%
DNLI -1.21%
DNTH -2.85%
DOMH 1.99%
DRMA 0.00%
DRMAW 0.00%
DRNA 0.00%
DRTS -1.32%
DRTSW 1.01%
DRUG 0.00%
DSGN 2.97%
DTIL -2.07%
DYAI -5.29%
EARS -1.77%
EDIT 0.20%
EDSA 1.04%
EFTR -3.13%
EFTRW -0.26%
EIGR 0.00%
ELAB 1.44%
ELDN -6.93%
ELEV -7.89%
ELOX -12.50%
ELTX -2.33%
ELVN -0.65%
ELYM -13.05%
ENGN -3.89%
ENGNW -7.06%
ENLV -3.47%
ENOB 1.79%
ENSC -0.55%
ENTA -6.00%
ENTO -2.80%
ENTX 0.00%
ENVB -4.64%
EPIX -8.75%
EPRX -0.19%
EPZM 0.00%
EQ 0.50%
EQRX -2.09%
EQRXW 0.00%
ERAS -7.83%
ERNA 2.60%
ERYP 1.30%
ESLA -6.38%
ESLAW -9.25%
ETNB 1.03%
ETON -5.90%
ETTX 0.00%
EVAX -19.54%
EVGN -2.14%
EVLO 50.00%
EWTX -0.80%
EXAI 1.19%
EXEL 0.18%
EYEG -0.43%
EYEN 1.57%
EYPT -3.94%
FATE -1.11%
FBIO 1.60%
FBIOP -1.05%
FBLG -5.34%
FBRX -7.46%
FDMT 0.72%
FENC 0.74%
FGEN -5.36%
FHTX 9.52%
FIXX 0.77%
FMTX 0.00%
FNCH -6.25%
FOLD -0.99%
FREQ 4.76%
FRLN 0.15%
FRTX -0.54%
FSTX 0.00%
FTRE 0.38%
FULC -6.04%
FUSN 0.00%
FWBI 4.59%
FWP 0.00%
GALT -4.58%
GANX 6.45%
GBIO 6.57%
GBT 0.01%
GDTC 2.16%
GERN -4.11%
GHRS 3.42%
GLMD -6.66%
GLPG 1.18%
GLSI 18.16%
GLTO -4.90%
GLUE -4.18%
GLYC -9.70%
GMAB -1.57%
GMDA 0.00%
GMTX 0.00%
GNCA -85.71%
GNFT 0.14%
GNLX 1.27%
GNPX 1.84%
GNTA -0.60%
GOSS 0.02%
GOVX -7.50%
GOVXW -24.72%
GPCR 0.85%
GRAY -10.80%
GRCL 0.05%
GRNA -0.03%
GRNAW 8.91%
GRPH -2.75%
GRTS -2.71%
GRTX -4.26%
GTHX -3.96%
GUTS -3.90%
GXGXW 41.67%
GYRE 4.44%
HALO 0.32%
HARP 0.09%
HCWB -9.73%
HEPA -6.36%
HGEN -84.62%
HILS 5.66%
HLVX 1.33%
HOOK -4.04%
HOTH -3.73%
HOWL 3.99%
HRMY 1.10%
HRTX -10.42%
HSTO 62.16%
HUMA -12.20%
HUMAW -5.97%
IBRX -2.18%
ICCC 2.84%
ICPT 0.21%
ICU 1.30%
ICUCW -10.39%
ICVX -0.91%
IDRA -23.04%
IDYA -1.44%
IFRX -3.21%
IGMS 0.41%
IKNA -0.57%
IKT 8.90%
IMAB -1.09%
IMCR -3.82%
IMGN 0.02%
IMGO 0.00%
IMMP -0.74%
IMMX -0.49%
IMNM -11.86%
IMNN -1.80%
IMPL -27.27%
IMRA 15.96%
IMRN -2.78%
IMRX 1.66%
IMTX -0.08%
IMTXW -2.70%
IMUX -4.20%
IMV 0.00%
IMVT 3.08%
INAB -8.26%
INBX -9.62%
INCY 0.93%
INDP 7.98%
INFI -52.38%
INKT -1.05%
INM -2.58%
INMB -2.47%
INO -1.65%
INSM 1.22%
INTS -5.63%
INVA 1.57%
INZY -2.95%
IOBT -6.11%
IONS 0.27%
IOVA -0.98%
IPA 0.48%
IPHA -10.64%
IPSC 0.64%
IRON -3.05%
ISEE 0.38%
ITOS -6.04%
ITRM -1.74%
IVA -10.10%
IVVD -6.96%
JAGX -6.67%
JANX -4.57%
JAZZ 1.43%
JNCE 0.00%
JSPR -2.80%
JSPRW 2.33%
JUNS 0.00%
JUNSW 0%
KA 4.11%
KALV -2.07%
KDNY 0.22%
KMPH -0.34%
KNSA -1.28%
KNTE -0.38%
KOD -4.27%
KPRX -21.08%
KPTI 1.69%
KRBP 4.17%
KRON -3.70%
KROS -9.68%
KRRO -16.54%
KRTX 0.03%
KRYS -0.04%
KTRA -2.35%
KTTA -2.85%
KTTAW 8.62%
KURA -0.62%
KYMR -4.42%
KYTX -17.21%
KZIA -1.29%
KZR -2.71%
LABP 0.57%
LBPH 1.67%
LBPS 0.00%
LBPSW 14.81%
LEGN -2.24%
LENZ -0.54%
LEXX -5.18%
LEXXW -9.42%
LGND 0.72%
LGNDV 0.00%
LGVN -24.76%
LIAN 0.00%
LIFE 2.70%
LIPO -1.23%
LIXT 0.40%
LIXTW 27.74%
LJPC -0.32%
LMNL 0.12%
LOGC 2.76%
LPCN 12.64%
LPTX -1.90%
LQDA 3.01%
LRMR -14.91%
LSTA -4.97%
LTRN -8.57%
LUMO -2.95%
LVTX -9.52%
LXEO -6.50%
LXRX -5.49%
LYEL -8.05%
LYRA -8.37%
MACK 0.00%
MBIO 476.92%
MBRX -4.83%
MCRB -5.28%
MDGL -0.31%
MDNA -13.16%
MDWD 1.00%
MDXG 0.59%
MEIP 1.41%
MESO -0.55%
MGNX -4.03%
MGTA -7.74%
MGTX -2.23%
MGX -24.14%
MIRM 27.31%
MIRO 0.59%
MIST -1.42%
MITO 0.00%
MLEC -4.55%
MLECW 9.20%
MLND -5.36%
MLTX -2.99%
MLYS -3.02%
MNKD -1.04%
MNMD -3.36%
MNOV 0.00%
MNPR -8.51%
MOLN 8.81%
MOR 0.88%
MORF -1.25%
MREO 0.00%
MRKR 16.59%
MRNA -1.52%
MRNS -1.02%
MRSN -1.45%
MRTX -0.17%
MRUS -1.38%
MRVI -3.99%
MTCR -1.29%
MTEM 1.54%
MTP -18.50%
MURA 2.17%
MYMD 4.19%
NAMS -7.03%
NAMSW -7.61%
NAUT 0.00%
NBRV 0.71%
NBSE -1.56%
NBTX 4.77%
NCNA -1.64%
NERV 8.96%
NEXI 0.00%
NGM -1.28%
NGNE -6.08%
NKGN -4.44%
NKGNW 39.76%
NKTR 0.00%
NKTX -5.66%
NLSP 30.09%
NLSPW -16.67%
NMRA -4.09%
NMTR -42.97%
NOVN -24.84%
NRBO 0.45%
NRIX 0.72%
NRSN -3.82%
NRSNW 6.50%
NRXP 0.99%
NRXPW -15.65%
NRXS -6.06%
NTBL 13.82%
NTEC -12.45%
NTHI 0%
NTLA 0.08%
NTRBW -6.25%
NUVL -0.77%
NVAX -2.43%
NVCT 1.18%
NVIV -34.28%
NXTC -10.63%
NYMX -0.05%
OABI 0.95%
OABIW 13.46%
OBIO 0.88%
OBSV 0.00%
OCEA 10.64%
OCGN -5.63%
OCS -1.09%
OCUL -4.35%
OCUP 1.82%
ODT -4.27%
OKYO 0.00%
OLMA -3.96%
OMER -0.49%
OMGA -8.37%
ONCO 12.54%
ONCR -3.08%
ONCS 31.87%
ONCT -0.12%
ONCY -0.98%
ONTX -0.47%
ONVO 0.62%
OPNT 0.00%
OPT -5.51%
ORGS -1.72%
ORIC -0.67%
ORMP -0.44%
ORPH 0.00%
ORTX 0.30%
OSMT -1.77%
OTIC -92.64%
OTLK -1.43%
OVID -76.00%
OYST 0.00%
PALI 0.86%
PASG -3.81%
PBLA 9.76%
PBM -0.02%
PBYI 2.89%
PCSA 5.71%
PCVX -1.45%
PDSB -4.13%
PEPG 0.70%
PGEN 0.00%
PHAR 2.17%
PHAS 0.00%
PHAT 3.08%
PHIO 4.14%
PHIOW 36.47%
PHVS -0.53%
PHXM -5.20%
PIRS -5.64%
PKBO 0.00%
PKBOW 999 900.00%
PLRX -5.08%
PLUR 0.00%
PMN -5.59%
PMVP -1.20%
PNT 0.16%
PPBT -11.48%
PRAX -6.21%
PRDS 0.93%
PRLD 0.77%
PROG -3.47%
PROK 6.96%
PRQR -3.41%
PRTA -0.20%
PRTC -0.72%
PRTG -1.96%
PRTK 1.83%
PRVB 0.00%
PSTI -2.91%
PSTV 0.00%
PSTX 1.81%
PTCT -1.14%
PTE -0.82%
PTGX -2.76%
PTIXW 2.50%
PULM 3.72%
PXMD -1.92%
PYPD -0.36%
PYXS -3.43%
QLGN -11.72%
QNCX 0.00%
QNRX -10.97%
QSI -2.92%
QSIAW 0.00%
QTTB 3.82%
QURE -4.09%
RAIN -1.63%
RANI -5.46%
RAPT -0.30%
RARE 1.92%
RCKT -3.02%
REGN 0.85%
RENB -3.05%
REPL -6.63%
RETA 0.02%
REUN -0.89%
REVB 1.36%
REVBU 3.46%
REVBW 25.20%
RGLS -1.66%
RGNX -6.20%
RIGL -2.79%
RLAY -3.01%
RLMD -0.33%
RLYB -6.15%
RNA -0.10%
RNAC -14.55%
RNAZ -5.83%
RNXT 14.41%
ROIV 0.28%
ROIVW 4.56%
RPHM -0.60%
RPRX -1.15%
RPTX 0.00%
RUBY 2.70%
RVLP -32.05%
RVMD -3.94%
RVMDW -23.93%
RVNC -0.71%
RVPH -0.68%
RVPHW 11.54%
RXDX 0.09%
RXRX 1.19%
RYTM -3.76%
RYZB 0.02%
RZLT -2.53%
SABS 3.17%
SABSW -32.14%
SAGE -6.08%
SANA -1.32%
SAVA 0.81%
SAVAW 0.00%
SBBP 1.52%
SBTX 1.03%
SCNI 60.46%
SCPH -1.69%
SCPS 0.00%
SEEL -4.62%
SEER -3.37%
SELB -8.00%
SESN 7.29%
SGEN -0.07%
SGMO -17.30%
SGMT 1.93%
SGTX -2.56%
SIOX 22.63%
SLDB -5.44%
SLGL -2.22%
SLN -1.55%
SLNO 0.19%
SLRX 2.89%
SLS -16.67%
SMMT -5.84%
SNDX -1.14%
SNGX -5.91%
SNPX -3.97%
SONN -4.75%
SPPI -0.49%
SPRB 0.49%
SPRC -3.16%
SPRO -5.88%
SRNE 20.00%
SRPT -4.89%
SRRA 0.00%
SRRK -7.09%
SRZN -1.70%
STAB 0.00%
STOK -4.00%
STRO -7.51%
STSA 0.00%
STTK -19.55%
SURF -0.93%
SVRA -5.15%
SWTX -4.88%
SYBX -0.63%
SYRS -4.83%
TALS -0.73%
TARA -0.78%
TARS -6.91%
TBPH -0.59%
TCBP -8.64%
TCDA 0.00%
TCON 6.35%
TCRR 0.00%
TCRT 1.05%
TCRX -11.43%
TECH -1.40%
TENX -3.43%
TERN -2.93%
TFFP 0.52%
TGTX 0.12%
THRX 0.12%
TIL -2.06%
TLC 0.00%
TLSA 5.78%
TNGX 5.04%
TNXP -2.61%
TNYA -1.79%
TPST 0.34%
TRDA -3.61%
TRVI 2.08%
TRVN -1.88%
TSHA 1.51%
TSVT 3.29%
TTNP 1.45%
TVTX 2.23%
TYRA -8.69%
UBX -4.17%
UNCY 0.22%
URGN -4.79%
UTHR 3.12%
VACC 11.36%
VALN -1.55%
VAXX -0.11%
VBIV -3.61%
VBLT -8.77%
VCEL -1.37%
VCNX -3.70%
VCYT 1.96%
VERA -0.83%
VERU 2.29%
VERV -2.77%
VIGL -2.08%
VINC -4.90%
VIR -5.85%
VIRI 4.95%
VIRX -3.62%
VKTX 0.00%
VLON -13.04%
VNDA 1.76%
VOR 1.74%
VRCA 0.49%
VRDN -1.93%
VRNA 10.04%
VRPX 10.77%
VRTX -1.46%
VSTM 0.00%
VTGN -2.84%
VTVT -0.10%
VTYX -4.51%
VXRT -8.25%
VYGR -2.94%
VYNE 2.16%
VYNT 7.78%
WINT 7.98%
WVE -3.85%
XBIO 6.75%
XBIT -0.33%
XCUR -3.10%
XENE -1.75%
XERS -0.91%
XFOR -2.75%
XLO -6.86%
XLRN 0.00%
XNCR -5.15%
XOMA -4.31%
XOMAO 0.68%
XOMAP -0.14%
XRTX 1.96%
YMAB -1.34%
ZGNX 0.00%
ZIOP -0.88%
ZLAB 1.55%
ZNTL -5.09%
ZSAN 0.00%
Koreliacija (AI algo v.1.1b): Undervalued: 0.07% $18.31 paired level. (Algoritmas realiuoju laiku stebi didžiausią koreliaciją turinčių akcijų pokyčius ir suteikia momentinę informaciją)

Tūris Koreliacija

Ilgas: 0.33 (neutral)
Trumpas: 0.75 (moderate)
Signal:(81.838) Neutral

MorphoSys AG Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
MSVB0.97
VERA0.96
INBK0.937
APPF0.935
BRAC0.922
RILYO0.918
YMAB0.918
GHSI0.917
CVLT0.917
ASML0.914
10 Labiausiai neigiamai susiję koreliacijos
TKLF-0.968
REVB-0.961
GOVX-0.953
EXTR-0.943
COLB-0.943
BIOL-0.941
RDHL-0.939
DCOM-0.939
INDB-0.938
SGML-0.937

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

MorphoSys AG Koreliacija - Valiuta/Žaliavos

The country flag -0.36
( neutral )
The country flag -0.42
( neutral )
The country flag 0.00
( neutral )
The country flag 0.05
( neutral )
The country flag -0.38
( neutral )
The country flag 0.74
( moderate )

MorphoSys AG Finansinės ataskaitos

Annual 2023
Pajamos: $238.28M
Bruto pelnas: $179.92M (75.51 %)
EPS: $-1.380
FY 2023
Pajamos: $238.28M
Bruto pelnas: $179.92M (75.51 %)
EPS: $-1.380
FY 2022
Pajamos: $278.27M
Bruto pelnas: $229.65M (82.53 %)
EPS: $-4.42
FY 2021
Pajamos: $179.61M
Bruto pelnas: $147.42M (82.08 %)
EPS: $-3.85

Financial Reports:

No articles found.

MorphoSys AG Options Data

Calls

Contract Name Last Trade Date (EDT) Strike Last Price Bid Ask Change % Change Volume Open Interest Implied Volatility Strike Date
No data available

Puts

Contract Name Last Trade Date (EDT) Strike Last Price Bid Ask Change % Change Volume Open Interest Implied Volatility Strike Date
No data available

MorphoSys AG

MorphoSys AG, a commercial-stage biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutic antibodies for patients suffering from cancer and autoimmune diseases in the United States. It offers Tafasitamab, an antibody for the treatment of B cell malignancies, including diffuse large B-cell lymphoma, follicular lymphoma, and marginal zone lymphoma. The company also develops Pelabresib, a small molecule that is in Phase II clinical trial to treat myelofibrosis; Felzartamab, an antibody directed against CD38, which is in Phase I/II clinical trials for the treatment of anti-PLA2R-positive membranous nephropathy, an autoimmune disease; and CPI-0209, a small molecule that is in Phase I/II designed to promote anti-tumor activity by inhibiting EZH2. In addition, it develops Gantenerumab, an antibody for the treatment of Alzheimer's diseases through its pharmaceutical partners; Otilimab, an antibody for rheumatoid arthritis; Tremfya, an antibody to treat psoriasis, psoriatic arthritis, and palmoplantar pustulosis; and MOR210/TJ210, an antibody to treat immuno-oncology and autoimmune diseases. MorphoSys AG has a regional licensing agreement with I-Mab Biopharma to develop and commercialize felzartamab in China, Taiwan, Hong Kong, and Macau; a strategic alliance with the LEO Pharma; a joint collaboration and license agreement with Incyte Corporation to develop and commercialize MorphoSys investigational compound tafasitamab; and a clinical collaboration with Incyte Corporation and Xencor, Inc. to investigate the combination of tafasitamab, plamotamab, and lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma, and relapsed or refractory follicular lymphoma. The company was founded in 1992 and is headquartered in Planegg, Germany.

Apie Signalai gyvai

Šiame puslapyje pateikti tiesioginiai signalai padeda nustatyti, kada PIRKTI ar PARDUOTI NA. Signalai vėluoja 1 minutę; kaip ir su visais rinkos signalais, taip ir su šiais, visuomet yra klaidų tikimybė.

Tiesioginiai prekybos signalai nėra apibrėžti, todėl getagraph.com neprisiima atsakomybės už jokius veiksmus, kurių buvo imtasi žinant šiuos signalus, kaip aprašyta Naudojimo sąlygose. Signalai yra pagrįsti įvairiais techninės analizės rodikliais.

Total Execution Time: 1.4066140651703 seconds
Number of API calls: 3
Number of DB calls: 9